Cargando…

Response to lorlatinib on a patient with ALK‐rearranged non‐small cell lung cancer harboring 1151Tins mutation with uterine metastasis

We describe a case of an anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer with development of uterine metastasis after crizotinib and alectinib treatment. Gene analysis from the tissue of uterine metastasis revealed the presence of 1151Tins, which was considered to be a crizoti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kobayashi, Takashi, Kanda, Shintaro, Fukushima, Toshirou, Noguchi, Takuro, Sekiguchi, Nodoka, Koizumi, Tomonobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365006/ https://www.ncbi.nlm.nih.gov/pubmed/34184417 http://dx.doi.org/10.1111/1759-7714.14056

Ejemplares similares

Intra‐oesophageal invasion of thymoma
por: Ozawa, Makiko, et al.
Publicado: (2019)

Primary mediastinal germ cell tumors ‐ A retrospective analysis of >30 years of experience in a single institution
por: Koizumi, Tomonobu, et al.
Publicado: (2021)

Late and Rapid Relapse in Mediastinum from Testicular Germ Cell Tumor Stage I Over 13 Years after Surgery
por: Fukushima, Toshirou, et al.
Publicado: (2019)

Giant paratesticular liposarcoma with lung metastases: a case report and review of the literature
por: Noguchi, Takuro, et al.
Publicado: (2020)

A Rare Distant Metastasis of Papillary Cystadenocarcinoma Arising from Maxillary Gingiva
por: Nishimaki, Fumihiro, et al.
Publicado: (2020)

Posterior mediastinal ganglioneuroblastoma in an adolescent: A case report and review
por: Sekiguchi, Nodoka, et al.
Publicado: (2019)

Targeted therapy with trastuzumab for epidermal growth factor receptor 2 (HER2)-positive advanced salivary duct carcinoma: A case report
por: Gibo, Takahiko, et al.
Publicado: (2019)

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer
por: Mizuta, Hayato, et al.
Publicado: (2021)

Fluorine‐18‐fluorodeoxyglucose‐positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal‐related events
por: Gomi, Daisuke, et al.
Publicado: (2019)

Gastric cancer initially presenting as bone metastasis: Two case reports and a literature review
por: Gomi, Daisuke, et al.
Publicado: (2018)

CCR4-positive peripheral T-cell lymphoma presenting as eosinophilic pneumonia and developing from prolonged pustular psoriasis
por: Sekiguchi, Nodoka, et al.
Publicado: (2021)

ACTH‐producing thymic neuroendocrine tumor initially presenting as psychosis: A case report and literature review
por: Okumura, Taiki, et al.
Publicado: (2019)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
por: Koizumi, Tomonobu, et al.
Publicado: (2016)

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer
por: Katayama, Yuki, et al.
Publicado: (2023)

Increased carbohydrate antigen 19‐9 expression in a thymic neuroendocrine tumor
por: Shimizu, Yuki, et al.
Publicado: (2021)

Successful Response to Cyclophosphamide, Vincristine, and Dacarbazine Chemotherapy in a Patient with Metastatic Carotid Body Paraganglioma
por: Yamada, Hiroki, et al.
Publicado: (2021)

Serial Cancer Development Three Times in a Patient with Fanconi Anemia
por: Yanagisawa, Katsuya, et al.
Publicado: (2021)

Relapsed and unresectable inflammatory myofibroblastic tumor responded to chemotherapy: A case report and review of the literature
por: Maruyama, Yasuhiro, et al.
Publicado: (2017)

Direct Intraesophageal Growth from Metastatic Mediastinal Lymphadenopathy in Thymic Carcinoma
por: Kanazawa, Hiroki, et al.
Publicado: (2020)

Syndrome of Inappropriate Antidiuretic Hormone Secretion as the Initial Presentation in a Patient with Stage I Small-cell Lung Cancer
por: Koizumi, Tomonobu, et al.
Publicado: (2022)

Lorlatinib Versus Pemetrexed-Based Chemotherapy in Patients With ALK-rearranged NSCLC Previously Treated With Alectinib
por: Takeyasu, Yuki, et al.
Publicado: (2022)

Successful and long-term response to trastuzumab plus paclitaxel combination therapy in human epidermal growth factor receptor 2-positive extramammary Paget's disease: A case report and review of the literature
por: Ichiyama, Takashi, et al.
Publicado: (2017)

Successful Salvage Chemotherapy with Streptozocin in a Patient with Mediastinal Atypical Carcinoid Tumor Who Had Relapsed after Various Prior Therapies
por: Fukushima, Toshirou, et al.
Publicado: (2018)

Successful treatment with doxorubicin and ifosfamide for mediastinal malignant peripheral nerve sheath tumor with loss of H3K27me3 expression
por: Seno, Noriko, et al.
Publicado: (2017)

Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis
por: Hochmair, Maximilian J., et al.
Publicado: (2020)

Management of Oligoprogression in Patients with Metastatic NSCLC Harboring ALK Rearrangements
por: Pisano, Chiara, et al.
Publicado: (2022)

Uterine mesenchymal tumors harboring ALK fusions and response to ALK-targeted therapy
por: Kyi, Chrisann, et al.
Publicado: (2021)

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer
por: Shimizu, Yuki, et al.
Publicado: (2022)

Lorlatinib Tolerability and Association With Clinical Outcomes in Patients With Advanced ALK- or ROS1-Rearranged NSCLC: A Brief Report
por: Thummalapalli, Rohit, et al.
Publicado: (2023)

Signet Ring Cell Carcinoma of Unknown Primary Origin Detected Incidentally by Lymph Node Purification for Thyroid Carcinoma
por: Handa, Hideo, et al.
Publicado: (2017)

Endobronchial Metastases in Lung Cancer Harboring EML4-ALK Rearrangement
por: Ijichi, Miharu, et al.
Publicado: (2022)

Efficacy of lorlatinib treatment in ALK rearrangement lung cancer with severe symptomatic central nervous system metastases and poor performance status
por: Taketa, Tomoyo, et al.
Publicado: (2021)

Clinical Responses to Crizotinib, Alectinib, and Lorlatinib in a Metastatic Colorectal Carcinoma Patient With ALK Gene Rearrangement: A Case Report
por: He, Xi, et al.
Publicado: (2021)

Pan‐HER inhibitors overcome lorlatinib resistance caused by NRG1/HER3 activation in ALK ‐rearranged lung cancer
por: Taniguchi, Hirokazu, et al.
Publicado: (2022)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

Response to ALK‐TKIs in a lung adenocarcinoma patient harboring dual DCTN1‐ALK and ALK‐CLIP4 rearrangements
por: Gao, Fangfang, et al.
Publicado: (2022)

Brain Penetration of the ROS1/ALK Inhibitor Lorlatinib Confirmed by PET
por: Collier, T. Lee, et al.
Publicado: (2017)

Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC
por: Toyozawa, Ryo, et al.
Publicado: (2020)

Safety and efficacy of lorlatinib against ALK-driven refractory or relapsed neuroblastoma
por: Suk, Yujin, et al.
Publicado: (2023)

Lorlatinib in ALK- or ROS1-rearranged non-small cell lung cancer: an international, multicenter, open-label phase 1 trial
por: Shaw, Alice T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_l1a6ll76mdeg88rvhnpc485s29